Illumina (ILMN) is a publicly traded Healthcare sector company. As of May 20, 2026, ILMN trades at $141.00 with a market cap of $21.41B and a P/E ratio of 25.43. ILMN moved +0.09% today. Year to date, ILMN is +5.46%; over the trailing twelve months it is +70.80%. Its 52-week range spans $68.70 to $156.66. Analyst consensus is neutral with an average price target of $141.42. Rallies surfaces ILMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Illumina Cuts Packaging 87%, Hits 10 Genomes Per Minute Sequencing Pace: Illumina’s 2025 Corporate Responsibility Report states its sequencing platforms processed over 10 human genomes per minute and supported global population-scale genomics initiatives through government and health system partnerships. The company cut product packaging by 87%, reduced Scope 1 and 2 emissions by 74% and secured 100% renewable electricity.
| Metric | Value |
|---|---|
| Price | $141.00 |
| Market Cap | $21.41B |
| P/E Ratio | 25.43 |
| EPS | $5.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $156.66 |
| 52-Week Low | $68.70 |
| Volume | 1.24M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.39B |
| Net Income | $853.00M |
| Gross Margin | 66.20% |
12 analysts cover ILMN: 0 strong buy, 6 buy, 3 hold, 3 sell, 0 strong sell. Consensus rating is neutral. Average price target: $141.42.